Two Decades Outcomes of Posttransplant Immunoglobulin A Nephropathy in Live Donor Renal Transplantation

Overview

Journal Indian J Nephrol

Specialty Nephrology

Date 2022 Aug 15

PMID 35967532

Authors

Mudit Khurana

Narayan Prasad

Manas Behera

Monika Yachha

Ravi Kushwaha

Vinita Agarwal

Dharmendra Bhadauria

Anupama Kaul

Manas Patel

Manoj Jain

Affiliations

Soon will be listed here.

Abstract

Background: The data on long-term outcomes of posttransplant immunoglobulin A nephropathy (IgAN) are confounding and vary with geography and ethnicity worldwide. We aimed to study the long-term graft outcomes of patients with posttransplant IgAN in the northern Indian cohort.

Methods: The long-term graft outcomes of 51 live donor renal transplant recipients with biopsy-proven posttransplant IgAN (recurrence/de novo) were analyzed. The risk factors for graft failure in the posttransplant IgA groups were analyzed using the Cox regression analysis.

Results: Out of the total of 51 patients who had posttransplant IgAN, 40 patients had a biopsy-proven native kidney IgAN. The mean duration of the clinical presentation of posttransplant IgAN was 62.4 months (5.2 years) posttransplant. Proteinuria at the time of biopsy was 3.03 ± 2.2 g/day, and 41.2% had proteinuria of more than 3 g/day at the time of biopsy. The estimated 1, 5, 10, and 20 years patient survival was 98%, 95.4%, 75.9%, and 25.2%, respectively, and the estimated 1, 5, 10, and 20 years graft survival was 98%, 88.5%, 44.6%, and 11.9%, respectively, in patients who had posttransplant IgA. Many of the traditional risk factors associated with progression in native kidney IgAN, such as the degree of proteinuria, Oxford MEST (mesangial and endocapillary hypercellularity, segmental sclerosis, and interstitial fibrosis/tubular atrophy) scoring, recipient's age, and sex were not predictive of early graft failure among patients with posttransplant IgAN. In our cohort, the only significant graft failure predictor was serum creatinine at 5 years. Chronic antibody-mediated rejection (ABMR) was seen in 21.6% of patients with posttransplant IgAN. Whether this coexistence of chronic ABMR is an incidental finding or posttransplant IgAN predisposes to chronic ABMR requires further investigation.

Conclusion: Posttransplant IgAN is associated with poor long-term graft outcomes in live donor renal transplants. Proteinuria and MEST scoring were not predictive of graft failure in living donor posttransplant IgAN.

Citing Articles

Tubulo-interstitial inflammation increases the risk of graft loss after the recurrence of IgA nephropathy.

Rodrigo E, Quintana L, Vazquez-Sanchez T, Sanchez-Fructuoso A, Buxeda A, Gavela E Clin Kidney J. 2024; 17(1):sfad259.

PMID: 38186867 PMC: 10768752. DOI: 10.1093/ckj/sfad259.

References

Wang A, Lai F, Yu A, Lam P, Chow K, Choi P . Recurrent IgA nephropathy in renal transplant allografts. Am J Kidney Dis. 2001; 38(3):588-96. DOI: 10.1053/ajkd.2001.26885. View

Li X, Chen J, Cheng D, Ji S, Xie K, Ni X . [Clinicopathologic features and prognosis of patients with IgA nephropathy superimposed on transplant glomerulopathy]. Zhonghua Yi Xue Za Zhi. 2019; 99(12):889-894. DOI: 10.3760/cma.j.issn.0376-2491.2019.12.003. View

Briganti E, Russ G, McNeil J, Atkins R, Chadban S . Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002; 347(2):103-9. DOI: 10.1056/NEJMoa013036. View

Prakash S, Kanjanabuch T, Austin P, Croxford R, Hsu C, Choi A . Continental variations in IgA nephropathy among Asians. Clin Nephrol. 2008; 70(5):377-84. PMC: 2647332. DOI: 10.5414/cnp70377. View

Kamal Aziz A, Mousson C, Berthoux F, Ducloux D, Chalopin J . Renal transplantation outcome in selected recipients with IgA nephropathy as native disease: a bicentric study. Ann Transplant. 2012; 17(3):45-51. DOI: 10.12659/aot.883457. View

Andresdottir M, Hoitsma A, Assmann K, Wetzels J . Favorable outcome of renal transplantation in patients with IgA nephropathy. Clin Nephrol. 2001; 56(4):279-88. View

Frohnert P, Donadio Jr J, Velosa J, HOLLEY K, Sterioff S . The fate of renal transplants in patients with IgA nephropathy. Clin Transplant. 1997; 11(2):127-33. View

Han S, Huh W, Park S, Ahn C, Han J, Kim S . Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy. Transpl Int. 2009; 23(2):169-75. DOI: 10.1111/j.1432-2277.2009.00966.x. View

McDonald S, Russ G . Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches. Transplantation. 2006; 82(6):759-62. DOI: 10.1097/01.tp.0000230131.66971.45. View

10.

Chandrakantan A, Ratanapanichkich P, Said M, Barker C, Julian B . Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil. Nephrol Dial Transplant. 2005; 20(6):1214-21. DOI: 10.1093/ndt/gfh773. View

11.

Matsugami K, Naito T, Nitta K, Nihei H, Tanabe K, Toma H . [A clinicopathological study of recurrent IgA nephropathy following renal transplantation]. Nihon Jinzo Gakkai Shi. 1998; 40(5):322-8. View

12.

Hart A, Smith J, Skeans M, Gustafson S, Stewart D, Cherikh W . Kidney. Am J Transplant. 2016; 16 Suppl 2:11-46. PMC: 5541687. DOI: 10.1111/ajt.13666. View

13.

Hartung R, Livingston B, Excell L, Disney A, Woodroffe A . Recurrence of IgA deposits/disease in grafts. An Australian Registry Survey 1980-1990. Contrib Nephrol. 1995; 111:13-6; discussion 16-7. View

14.

Kim Y, Moon J, Jeong H, Kim M, Kim S, Choi K . Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. Transplantation. 2001; 71(2):233-8. DOI: 10.1097/00007890-200101270-00011. View

15.

Nijim S, Vujjini V, Alasfar S, Luo X, Orandi B, Delp C . Recurrent IgA Nephropathy After Kidney Transplantation. Transplant Proc. 2016; 48(8):2689-2694. DOI: 10.1016/j.transproceed.2016.08.011. View

16.

Kessler M, Hiesse C, Hestin D, Mayeux D, Boubenider K, Charpentier B . Recurrence of immunoglobulin A nephropathy after renal transplantation in the cyclosporine era. Am J Kidney Dis. 1996; 28(1):99-104. DOI: 10.1016/s0272-6386(96)90137-7. View

17.

Varma P, Hooda A, Sinha T, Chopra G, Karan S, Sethi G . Renal Transplantation - An Experience of 500 Patients. Med J Armed Forces India. 2016; 63(2):107-11. PMC: 4925376. DOI: 10.1016/S0377-1237(07)80049-9. View

18.

Moriyama T, Nitta K, Suzuki K, Honda K, Horita S, Uchida K . Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation. Clin Transplant. 2005; 19 Suppl 14:41-8. DOI: 10.1111/j.1399-0012.2005.00403.x. View

19.

Levy M, Berger J . Worldwide perspective of IgA nephropathy. Am J Kidney Dis. 1988; 12(5):340-7. DOI: 10.1016/s0272-6386(88)80021-0. View

20.

Bachman U, Biava C, Amend W, Feduska N, Melzer J, Salvatierra O . The clinical course of IgA-nephropathy and Henoch-Schönlein purpura following renal transplantation. Transplantation. 1986; 42(5):511-5. DOI: 10.1097/00007890-198611000-00014. View